Contact: Alana Rockland, W2O Group
TV Icon and Heart Disease Survivor Regis Philbin Joins Kowa Pharmaceuticals America, Inc. to Launch National Education Campaign Take Cholesterol to Heart
MONTGOMERY, Ala., October 3, 2017 — Kowa Pharmaceuticals America, Inc., a company focused primarily on cardiometabolic diseases, today announced the launch of the Take Cholesterol to Heart campaign in partnership with TV legend and heart disease survivor Regis Philbin and the American Academy of Family Physicians (AAFP) Foundation. High cholesterol affects over 100 million Americans and is a major risk factor for heart disease –the number 1 cause of death in the United States. To lower cholesterol, doctors often prescribe statins. Yet, despite the proven benefits of statin therapy in reducing heart disease, at least 50 percent or more of people on a statin medication discontinue it within one year after treatment initiation, and consistency of use decreases over time.1
Take Cholesterol to Heart encourages people to speak frankly with their doctor about their personal challenges staying on statin therapy so they can develop strategies to stick with this life-saving medication. Through the campaign, Regis Philbin, Kowa Pharmaceuticals America, Inc., and the AAFP Foundation aim to motivate people to fight heart disease with a simple message: stay on your heart-healthy routine and speak up before you stop your statin. Multiple statins are available, and by proactively having a frank discussion with their doctor, people can find a statin that fits their individualized needs.
“During my 50 plus years speaking to Americans in their living rooms, I’ve always talked from the heart, including about my heart disease and major heart surgeries,” said Regis Philbin, Emmy award-winner, TV legend, and host of Live with Regis and Kelly, Live with Regis and Kathie Lee, and Who Wants to Be a Millionaire? “A long career and the gift of time with my friends and family have been possible because I speak with my doctor regularly and stay on the right statin for me. Through the campaign, I hope to motivate and inspire others to make a commitment to their heart health and speak to their doctor before they stop their statin medication.”
To understand why people stop taking statins despite the serious risks of high cholesterol, Kowa Pharmaceuticals America, Inc., recently commissioned Harris Poll to survey over 5,000 Americans online aged 45 or older, who are diagnosed with high cholesterol and have ever taken a statin medication for it, including high-risk heart disease populations such as people with type 2 diabetes or high blood pressure and those age 65 years or older. ACTION: The Statin Survey (Understanding Patient Adherence and Concerns with Statins, and Medication Discussions with Physicians), one of the largest surveys of its kind, found:
“The ACTION survey results underscore the need for patients and physicians to have an open dialogue about statin therapy and cardiovascular disease prevention. Patients should feel comfortable asking their doctor questions so they understand which statin is most appropriate for them based on their individual health profile, including current medications and their heart disease risk factors,” said Craig A. Sponseller, MD, Chief Medical Officer at Kowa Pharmaceuticals America, Inc. “Statins are at the cornerstone of blood cholesterol management, and understanding how statins differ across patient profiles is critical. Along with our partners, we are proud to launch this new campaign that empowers patients to speak up and ask questions to their doctor regarding statin therapy rather than stopping treatment.”
As part of this national effort, the AAFP Foundation’s educational consumer resource, www.FamilyDoctor.org, now includes survey results and information about the importance of discussing your individual statin profile with your doctor.
High cholesterol is defined as total cholesterol ≥240 mg/dL based on guidelines from the National Institutes of Health (NIH). When cholesterol levels rise, thick, hard buildup can occur in the artery wall, narrowing arteries and slowing down or even blocking blood flow to the heart and brain. High cholesterol is a major risk for stroke and heart disease (the leading cause of death in America). It can be lowered through a healthy diet, exercise, and by taking a medication (like a statin) as recommended by a physician.
The goal of Take Cholesterol to Heart is to increase public understanding of high cholesterol as a key risk factor for heart disease and to provide strategies that empower people to stay on their doctor-prescribed statin medication. There are multiple statins available, and by maintaining an open dialogue with their doctor, people can help ensure that they are on an individualized treatment regimen including the statin that is most appropriate for them. For more information about the campaign and resources, visit www.TakeCholesteroltoHeart.com.
Harris Poll conducted ACTION: The Statin Survey (Understanding Patient Adherence and Concerns with Statins, and Medication Discussions with Physicians) online on behalf of Kowa Pharmaceuticals America, Inc., from July 7 to August 4, 2017, among 5,014 US adults age 45 or older who had been diagnosed with high cholesterol and had ever used a statin to treat high cholesterol. This online survey is not based on a probability sample and therefore no estimate of theoretical sampling error can be calculated.
The Foundation serves as the philanthropic arm of the American Academy of Family Physicians. Its mission is to advance the values of Family Medicine by promoting humanitarian, educational, and scientific initiatives that improve the health of all people.
Kowa Company, Ltd. (Kowa) is a privately held, multinational company headquartered in Nagoya, Japan. Established in 1894, Kowa is actively engaged in various business fields, including the trading of textiles, machinery, and construction materials, in addition to the manufacturing and sales of medicines, medical equipment, and energy saving products. Kowa's pharmaceutical division is focused on research and development for cardiovascular therapeutics (dyslipidemia, type 2 diabetes, and atherosclerosis), ophthalmology, and anti-inflammatory agents.
Kowa Pharmaceuticals America, Inc., headquartered in Montgomery, AL, is focused primarily in the area of cardiometabolic therapeutics. Established in September 2008, Kowa Pharmaceuticals America focuses its efforts on the successful commercialization of its current and near-term portfolio of pharmaceutical products and business development activities. For more information about Kowa Pharmaceuticals America, visit www.kowapharma.com.